SCHEMBL29327974

SCHEMBL29327974

CCc1ccc(-c2nc3ccc(NC(=O)c4cc(C#N)ncc4S(C)(=O)=O)cn3n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 10/20 0.42
▸ NAMPT P43490 4/20 0.38
▸ PPARG P37231 1/20 0.37
▸ FFAR1 O14842 1/20 0.37
▸ TP53 P04637 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KLF5 Q13887 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327882 0.87 PPARG (0.47) PDE10ANAMPTPPARGFFAR1TP53
SCHEMBL29327947 0.84 PDE10A (0.40) PDE10ANAMPTPPARGFFAR1TP53
SCHEMBL29327994 0.84 PDE10A (0.42) PDE10ANAMPTPPARGFFAR1TP53
SCHEMBL29327917 0.81 PPARG (0.45) PDE10ANAMPTPPARGFFAR1TP53
SCHEMBL29327967 0.78 NPC1 (0.40) PPARGTP53MEN1NPC1KMT2A
SCHEMBL29327971 0.78 NPC1 (0.40) PPARGTP53MEN1NPC1KMT2A
SCHEMBL29327968 0.78 NPC1 (0.37) PPARGTP53MEN1NPC1KMT2A
SCHEMBL29327769 0.78 PPARG (0.54) PPARGTP53MEN1NPC1KMT2A
SCHEMBL29327747 0.78 PPARG (0.62) PPARGTP53MEN1NPC1KMT2A
SCHEMBL29327781 0.77 PPARG (0.54) NAMPTPPARGTP53MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PDE10A 255/4885NAMPT 1003/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback